Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

NCT02670109 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Invasive Breast Carcinoma
Residual Tumor

Interventions

DRUG: Carmustine
DRUG: Cyclophosphamide
DRUG: Carboplatin
PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
DRUG: Busulfan

Sponsor

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran